Research progress of tenofovir alafenamide in blocking mother-to-child transmission of hepatitis B virus / 中国临床药理学与治疗学
Chinese Journal of Clinical Pharmacology and Therapeutics
; (12): 578-582, 2023.
Article
in Zh
| WPRIM
| ID: wpr-1014642
Responsible library:
WPRO
ABSTRACT
Hepatitis B virus (HBV) infection is a global public health problem, and the prevention of mother-to-child transmission (MTCT) is an important intervention method. As a new nucleoside reverse transcriptase inhibitor, tenofovir alafenamide (TAF) has the characteristics of strong liver targeting and low peripheral blood exposure. Although it has been used in the treatment of chronic hepatitis B widely, its application in blocking mother-to-child transmission of HBV is still limited. This paper reviews the characteristics of TAF, the effects of TAF on infants and pregnant women, in order to provide new ideas for the prevention of mother-to-child transmission of HBV.
Full text:
1
Index:
WPRIM
Language:
Zh
Journal:
Chinese Journal of Clinical Pharmacology and Therapeutics
Year:
2023
Type:
Article